| NAD (P) H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity L Wojnowski, B Kulle, M Schirmer, G Schlüter, A Schmidt, ... Circulation 112 (24), 3754-3762, 2005 | 575 | 2005 |
| Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication J Kirchheiner, H Schmidt, M Tzvetkov, J Keulen, J Lötsch, I Roots, ... The pharmacogenomics journal 7 (4), 257-265, 2007 | 536 | 2007 |
| The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin MV Tzvetkov, SV Vormfelde, D Balen, I Meineke, T Schmidt, D Sehrt, ... Clinical Pharmacology & Therapeutics 86 (3), 299-306, 2009 | 397 | 2009 |
| Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration MV Tzvetkov, JN dos Santos Pereira, I Meineke, AR Saadatmand, ... Biochemical pharmacology 86 (5), 666-678, 2013 | 198 | 2013 |
| Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics J Kirchheiner, C Heesch, S Bauer, C Meisel, A Seringer, M Goldammer, ... Clinical Pharmacology & Therapeutics 76 (4), 302-312, 2004 | 167 | 2004 |
| Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron MV Tzvetkov, AR Saadatmand, K Bokelmann, I Meineke, R Kaiser, ... The pharmacogenomics journal 12 (1), 22-29, 2012 | 160 | 2012 |
| Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol MV Tzvetkov, AR Saadatmand, J Lötsch, I Tegeder, JC Stingl, ... Clinical Pharmacology & Therapeutics 90 (1), 143-150, 2011 | 150 | 2011 |
| Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment J Brockmöller, MV Tzvetkov European journal of clinical pharmacology 64, 133-157, 2008 | 124 | 2008 |
| Genetic dissection of trehalose biosynthesis in Corynebacterium glutamicum: inactivation of trehalose production leads to impaired growth and an altered cell wall … M Tzvetkov, C Klopprogge, O Zelder, W Liebl Microbiology 149 (7), 1659-1673, 2003 | 124 | 2003 |
| PharmGKB summary: tramadol pathway L Gong, UM Stamer, MV Tzvetkov, RB Altman, TE Klein Pharmacogenetics and genomics 24 (7), 374-380, 2014 | 123 | 2014 |
| Interindividual Variation in the Pharmacokinetics of Δ9‐Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9 C Sachse‐Seeboth, J Pfeil, D Sehrt, I Meineke, M Tzvetkov, E Bruns, ... Clinical Pharmacology & Therapeutics 85 (3), 273-276, 2009 | 113 | 2009 |
| The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family JN Dos Santos Pereira, S Tadjerpisheh, MA Abed, AR Saadatmand, ... The AAPS journal 16, 1247-1258, 2014 | 104 | 2014 |
| Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1 T Seitz, R Stalmann, N Dalila, J Chen, S Pojar, JN Dos Santos Pereira, ... Genome medicine 7, 1-23, 2015 | 99 | 2015 |
| AmpliChip CYP450 GeneChip®: a new gene chip that allows rapid and accurate CYP2D6 genotyping T Heller, J Kirchheiner, VW Armstrong, H Luthe, M Tzvetkov, ... Therapeutic drug monitoring 28 (5), 673-677, 2006 | 95 | 2006 |
| OCT1 mediates hepatic uptake of sumatriptan and loss‐of‐function OCT1 polymorphisms affect sumatriptan pharmacokinetics J Matthaei, D Kuron, F Faltraco, T Knoch, JN Dos Santos Pereira, ... Clinical Pharmacology & Therapeutics 99 (6), 633-641, 2016 | 91 | 2016 |
| Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment MV Tzvetkov, J Brockmöller, I Roots, J Kirchheiner Pharmacogenetics and genomics 18 (6), 495-506, 2008 | 90 | 2008 |
| Heritability of metoprolol and torsemide pharmacokinetics J Matthaei, J Brockmöller, MV Tzvetkov, D Sehrt, C Sachse‐Seeboth, ... Clinical Pharmacology & Therapeutics 98 (6), 611-621, 2015 | 72 | 2015 |
| Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency MV Tzvetkov, J Matthaei, S Pojar, F Faltraco, S Vogler, T Prukop, T Seitz, ... Clinical Pharmacology & Therapeutics 103 (5), 868-878, 2018 | 71 | 2018 |
| Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics D Sehrt, I Meineke, M Tzvetkov, S Gültepe, J Brockmöller Pharmacogenomics 12 (6), 783-795, 2011 | 71 | 2011 |
| Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine MV Tzvetkov, C Meineke, E Oetjen, K Hirsch-Ernst, J Brockmöller Gene 386 (1-2), 52-62, 2007 | 71 | 2007 |
